Capital Advisory Group Advisory Services’s Filana Therapeutics FLNA Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-125	Closed	-$8K	–	435
2021 Q3	$8K	Buy	+125	New	+$10.4K	﹤0.01%	423

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital Advisory Group Advisory Services's FLNA Position: Q4 2021 in Review

Capital Advisory Group Advisory Services sold out of Filana Therapeutics (FLNA) in Q4 2021, closing a stake of 125 shares — an estimated $8K sold.

Capital Advisory Group Advisory Services first reported a position in FLNA in Q3 2021 and held it in 1 quarter. The position peaked at $8K in Q3 2021. 171 funds tracked by Wall St. Rank hold FLNA as of Q4 2021.

Capital Advisory Group Advisory Services reported no remaining Filana Therapeutics position as of Q4 2021 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 125 Filana Therapeutics shares in Q4 2021, an estimated $8K.
Capital Advisory Group Advisory Services first reported a position in Filana Therapeutics in Q3 2021 and held it in 1 quarter.
Capital Advisory Group Advisory Services's Filana Therapeutics position peaked at $8K in Q3 2021.
171 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2021.

Based on Capital Advisory Group Advisory Services's 13F filing for Q4 2021, filed 15 Feb 2022.